Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Frequency of two MC subsets in human diseases

From: Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases

Disease

CD14 ++CD16 -(classical, phagocytic)

CD14 +CD16 +(Non-classical, inflammatory)

Functional changes associated with CD14 ++CD16 +MC expansion

PMID #

Rheumatoid Arthritis

No change

2.2% ↑

HLA-DR and CCR5↑ Counts of tender/swollen joints↑ Rheumatoid factors ↑

12384915

CAD

 

2.2% ↑

Serum TNFα ↑

15269840

CAD

 

8%  ↑

Plaque vulnerability↑

20684824

Atherosclerosis

8% ↓

8%  ↑

 

19461894

Hemophagocytic syndrome

 

31% ↑

Serum TNFα & IL-6↑

17619880

Crohn’s disease

 

5.7% ↑

 

17260384

Tumor/haematological malignancy

 

13.3% ↑

 

10209505

  1. Circulating classical (CD14++CD16-, also described as CD14brightCD16-, phagocytic) and non-classical (CD14+ CD16+, also described as CD14brightCD16+, inflammatory) MC counts were examined in human disease as indicated. The percentage change of MC subsets and some functional measurements are recorded. We used PMID # to cite individual manuscripts reporting these studies. MC, monocyte; AMI, acute myocardial infarction; CAD, coronary arterial disease; CKD, chronic kidney disease; HLA-DR, human leukocyte antigen DR (MHC-II, major histocompatibility complex class II); TNFα, tumor necrosis factor α; IL-6, interleukin 6; ↑, increase.
Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us